Sucampo Pharmaceuticals buys rare disease firm Vtesse

This article was originally published here

Sucampo Pharmaceuticals has acquired rare disease company Vtesse for upfront consideration of $200m.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply